Trials / Completed
CompletedNCT01884597
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Hawaii Pacific Health · Academic / Other
- Sex
- All
- Age
- 25 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
This is a 24-month study of ranibizumab (2.0 mg and 1.0 mg) in subjects with polypoidal choroidal vasculopathy as diagnosed by fluorescein/indocyanine green (FA/ICG) angiography.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | high-dose ranibizumab | 20mg ranibizumab vials, 0.05ml injected intravitreally, monthly |
| DRUG | ranibizumab | 3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2013-06-24
- Last updated
- 2017-10-09
- Results posted
- 2017-09-11
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01884597. Inclusion in this directory is not an endorsement.